Table 3 Lung function parameters of subjects with COPD (post-bronchodilator FEV1/FVC <0.70), asthma (wheezing + reversibility) and ACOS (post-bronchodilator FEV1/FVC <0.70 plus wheezing + reversibility)
From: Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
Variables | Asthma | COPD | ACOS | P-value |
|---|---|---|---|---|
(N = 43) | (N = 274) | (N = 35) | ||
Pre-bronchodilator FEV1, L | 2.3 (0.7) | 1.6 (0.7) | 1.4 (0.6) | <0.001 |
Pre-bronchodilator FEV1, % pred. | 84.3 (17.2) | 61.8 (22.6) | 50.7 (17.3) | <0.001 |
Post-bronchodilator FEV1, L | 2.6 (0.7) | 1.7 (0.7) | 1.6 (0.6) | <0.001 |
Post-bronchodilator FEV1, % pred. | 93.1 (15.8) | 64.7 (21.1) | 58.8 (18.6) | <0.001 |
FEV1 change, mL (absolute) | 237.7 (131.7) | 73.7 (176.7) | 215.4 (133.7) | <0.001 |
FEV1 change, % (relative) | 11.7 (10.1) | 8.1 (28.9) | 17.5 (13.3) | <0.001 |
Pre-bronchodilator FVC, L | 3.0 (0.9) | 2.6 (0.9) | 2.5 (0.8) | <0.001 |
Pre-bronchodilator FVC, % pred. | 84.0 (17.0) | 75.2 (19.3) | 66.7 (17.7) | <0.001 |
Post-bronchodilator FVC, L | 3.3 (0.9) | 2.7 (0.9) | 2.9 (0.8) | <0.001 |
Post-bronchodilator FVC, % pred. | 91.2 (15.4) | 79.0 (18.8) | 76.3 (17.7) | <0.001 |
FVC change, mL (absolute) | 244.9 (151.6) | 135.0 (238.0) | 346.6 (173.4) | <0.001 |
FVC change, % (relative) | 9.8 (9.5) | 6.2 (11.4) | 15.6 (9.3) | <0.001 |